Enan­ta is look­ing for a part­ner on its Covid pill af­ter a PhII study dis­ap­points

A biotech com­pa­ny with am­bi­tions to com­pete with Pfiz­er’s block­buster Covid-19 pill an­nounced mixed re­sults from a study of its ex­per­i­men­tal an­tivi­ral ther­a­py and won’t car­ry for­ward with de­vel­op­ment of the drug on its own.

Enan­ta Phar­ma­ceu­ti­cals said Mon­day that its pill, EDP-235, met its pri­ma­ry end­points of safe­ty and tol­er­a­bil­i­ty in its Phase II tri­al, dubbed SPRINT, but yield­ed mixed re­sults on its ef­fec­tive­ness. It failed to clear the virus faster than a place­bo and failed to speed up re­cov­ery of 14 symp­toms of Covid, al­though the com­pa­ny em­pha­sized that the treat­ment ap­peared to im­prove a sub­set of symp­toms.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER